Pharmafile Logo

Insurance policies

Biogen Idec building

ICER says price of Biogen’s Aduhelm should be much lower

US cost-effectiveness watchdog’s analysis estimates current annual list price of $56,000 could be reduced to $3,000 to $8,400

- PMLiVE

ICER to review the role of health insurers in determining patient access to prescription drugs

Non-profit research institute will evaluate how health insurance policies may harm patient access to treatment

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class

- PMLiVE

CGRP migraine drugs need prior approval for use, recommends ICER

Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors

- PMLiVE

Millennials’ disappointing medicine habits

Survey finds only 60% of 18-34 years olds take treatments as prescribed

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Pricing of Novartis’ Entresto about right, concludes ICER

Supports potential for $5bn-a-year brand 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links